Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司\*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2269)

## POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 5, 2019

The board (the "Board") of directors (the "Directors") of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司\* (the "Company") announces that at the annual general meeting of the Company held on June 5, 2019 (the "AGM"), all proposed resolutions as set out in the notice of the AGM dated May 6, 2019 were duly passed by the relevant shareholders of the Company by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 6, 2019 (the "Circular").

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditor of the Company for the year ended December 31, 2018.	993,916,720 (99.99%)	80,000 (0.01%)
2.	(a) To re-elect Dr. Weichang Zhou as executive Director.	988,566,401 (99.44%)	5,577,819 (0.56%)
	(b) To re-elect Mr. Yibing Wu as non-executive Director.	984,612,401 (99.04%)	9,531,819 (0.96%)
	(c) To re-elect Mr. Yanling Cao as non-executive Director.	984,665,401 (99.05%)	9,478,819 (0.95%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
3.	To authorise the Board or any duly authorised board committee to fix the Directors' remuneration for the year ending December 31, 2019.	981,593,147 (99.94%)	620,130 (0.06%)
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorise the Board or any duly authorised board committee to fix their remuneration.	992,784,720 (99.87%)	1,333,000 (0.13%)
5.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company.	694,677,482 (69.95%)	298,391,238 (30.05%)
6.	To grant a general mandate to the Directors to repurchase the shares of the Company.	991,442,720 (99.84%)	1,626,000 (0.16%)
7.	To extend the general mandate granted to the Directors to issue, allot and deal with the shares of the Company by adding thereto the shares to be repurchased by the Company.	699,670,135 (70.38%)	294,474,085 (29.62%)
8.	(a) To grant a specific mandate to the Directors to issue and allot the Connected Restricted Shares; and	847,662,542 (85.27%)	146,481,678 (14.73%)
	(b) To authorise any one of the Directors to take any action for and on behalf of the Company to carry out the issue and allotment of the Connected Restricted Shares under the specific mandate and the transactions contemplated thereunder.		
9.	To grant 986,500 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Dr. Zhisheng Chen.	847,663,542 (85.27%)	146,480,678 (14.73%)
10.	To grant 157,840 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Dr. Weichang Zhou.	847,663,542 (85.27%)	146,480,678 (14.73%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
11.	To grant 5,655 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Edward Hu.	825,079,735 (82.99%)	169,064,485 (17.01%)
12.	To grant 2,828 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. William Robert Keller.	825,079,735 (82.99%)	169,064,485 (17.01%)
13.	To grant 5,655 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Wo Felix Fong.	792,606,036 (79.73%)	201,538,184 (20.27%)

As at the date of the AGM, the total number of shares of the Company in issue, was 1,238,390,815 Shares.

As stated in the Circular, the respective Connected Grantees and their respective associates holding Shares were required to abstain and they had abstained from voting on the relevant resolutions numbered 8 to 13 in respect of the grant of Specific Mandate and the grant of Connected Restricted Shares to Connected Grantees proposed at the AGM.

To the best knowledge and belief of the Company, after making all reasonable enquiries, as at the date of the AGM, (i) Dr. Zhisheng Chen and his associates hold 711,418 Shares; (ii) Mr. Edward Hu and his associates hold 1,441,500 Shares; and (iii) each of Dr. Weichang Zhou, Mr. William Robert Keller and Mr. Wo Felix Fong, together with their respective associates do not hold any Shares.

Accordingly, as at the date of the AGM, the respective total number of Shares entitling the holders to attend and vote on resolutions numbered 1 to 7 were 1,238,390,815 Shares, being the total number of issued Shares as at the date of the AGM, and on resolutions numbered 8 to 13 were 1,236,237,897 Shares, 1,237,679,397 Shares, 1,238,390,815 Shares, 1,236,949,315 Shares, 1,238,390,815 Shares and 1,238,390,815 Shares, respectively.

Save as disclosed above, there were no restrictions on any shareholders of the Company to cast votes on any of the resolutions proposed at the AGM. No shareholder of the Company has stated his/her/its intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, June 5, 2019

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

\* For identification purpose only